Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03849963 · ClinicalTrials.gov registry record
Imaging Oxidative Metabolism and Neurotransmitter Synthesis in the Human Brain
A clinical trial of Brain Metabolism, sponsored by University of Texas Southwestern Medical Center.
- Recruiting
- Registry status
- 28
- Enrollment target
- 1
- Study location
NCT03849963: Recruiting study of Brain Metabolism, sponsored by University of Texas Southwestern Medical Center.
NCT03849963 is a study of Brain Metabolism that is actively recruiting participants, run by University of Texas Southwestern Medical Center. The registered enrollment target is 28 participants. The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03849963, a study of Brain Metabolism, is actively recruiting participants, sponsored by University of Texas Southwestern Medical Center.
- RECRUITING
- Registry status
- 28 participants
- Enrollment target
- 1
- Study location
Study Summary
Investigators propose to develop hyperpolarized \[13C\]-labeled pyruvate as potential imaging probes to assess two essential in vivo processes in cerebral metabolism: oxidative metabolism and synthesis of a neurotransmitter in this observational study.
Primary Outcome
Product ratios (Bicarbonate/Lactate, Glutamate/Lactate) will be acquired from the hyperpolarized 13C imaging
Conditions Studied
Study Locations (1)
Texas
- UT Southwestern - Advanced Imaging Research Center - Dallas
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 28 participants |
| Start Date | 2030-07-30 |
| Est. Completion | 2030-12-31 |
What NCT03849963 shows while recruiting
NCT03849963 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 28 participants, a relatively small participant target.
The record links to 1 condition, with Brain Metabolism appearing as the primary indexed condition, and to 0 interventions.
NCT03849963 reports a single indexed study location in Texas.
Frequently Asked Questions
What is clinical trial NCT03849963 about?
NCT03849963 is a clinical study titled "Imaging Oxidative Metabolism and Neurotransmitter Synthesis in the Human Brain". Investigators propose to develop hyperpolarized \[13C\]-labeled pyruvate as potential imaging probes to assess two essential in vivo processes in cerebral metabolism: oxidative metabolism and synthesis of a neurotransmitter in this observational study.
What is the current status of trial NCT03849963?
This trial is currently recruiting. The enrollment target is 28 participants. The study started on 2030-07-30. Estimated completion is 2030-12-31.
What conditions does trial NCT03849963 study?
This clinical trial studies the following conditions: Brain Metabolism.
Who is sponsoring clinical trial NCT03849963?
This trial is sponsored by University of Texas Southwestern Medical Center, which has 837 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03849963 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03471117 · 28 participants · Phase 4
Pioglitazone to Reduce Sympathetic Overactivity in CKD Patients
- NCT03523975 · 28 participants · Phase 1
Venetoclax, Lenalidomide and Rituximab in Patients With Previously Untreated Mantle Cell Lymphoma
- NCT03608631 · 28 participants · Phase 1
iExosomes in Treating Participants With Metastatic Pancreas Cancer With KrasG12D Mutation
- NCT03810651 · 28 participants · Early Phase 1
Pencil Beam Scanning in Patients With Renal Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI